• Teleflex completed enrollment in the BIOMAG-LL study of its Freesolve resorbable magnesium scaffold for longer coronary lesions.
• No results have been presented; the trial plans follow-ups through 60 months, with an initial 12-month clinical endpoint.
• The study is designed to assess safety and clinical performance of longer scaffold sizes intended to reduce reliance on permanent stents.
• The longer-length devices are also being evaluated in the ongoing BIOMAG-III pivotal trial now enrolling in the US and other markets.
• Freesolve is currently marketed only in CE-mark accepting countries, leaving US commercialization tied to future clinical outcomes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teleflex Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610120630BIZWIRE_USPR_____20261012_BW745636) on October 12, 2026, and is solely responsible for the information contained therein.